HDL and CETP inhibition: Will this define the future?

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 4, 2012, Pages 384-390

  Davidson, Michael H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CETP inhibitors; HDL

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TORCETRAPIB;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PARTICLE SIZE; POPULATION RESEARCH; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; STUDY DESIGN; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84865696926     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0191-8     Document Type: Review

References (24)

1. Barter PJ, Brewer Jr HB, Chapman MJ, et al. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160-7. (Pubitemid 36231923)
2. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atheroslerotic Events (ILLUMINATE) trial. Am J Cardiol. 2009;104(Suppl):10E-15E.
3. Davidson MH. Update on CETP inhibiton. J Clin Lipidol. 2010;4;394-98.
4. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrpib in patient with or at high risk for coronary heart disease. N Engl J med. 2010;363(25):2406-15
5. http://www.clinicaltrials.gov/ct2/show/NCT01252953.
6. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA. 2011;306:2099-109. This is the fourth CETP inhibitor to enter human trials and has an efficacy profile similar to anacetrapib
7. Schierer A, Been LF, Ralhan S, et al. Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort. Pharmacogenet Genomics. 2012;22:95-104.
8. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-88. This study suggests that the HDL-C-increasing effects of lower CETP activity is associated with reduced cardiovascular events
9. Brousseau ME, O'Connor Jr JJ, Ordovas JM, et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol. 2002;22:1148-54. (Pubitemid 34764866)
10. Dullaart RP, Sluiter WJ. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: An updated analysis. Pharmacogenomics. 2008;9:747-63.
11. Liu S, Schmitz C, Stampfer MJ, et al.: A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 2002, 161:469-474. Erratum in Atherosclerosis 2003, 166:415. Liu Simm [corrected to Liu Simin]. (Pubitemid 34219203)
12. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118(24)2506-14.
13. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053-9. (Pubitemid 27260323)
14. Nagano M, Yamashita S, Hirano K, et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb. 2004;11:110-21.
15. Okamura T, Sekikawa A, Kadowaki T, et al. Cholesteryl ester transfer protein, coronary calcium, and intimamedia thickness of the carotid artery in middle-age Japanese men. Am J Cardiol. 2009;104:818-22.
16. Zheng K, Zhang S, Zhang L, et al. Carriers of three polymorphisms of cholesteryl ester transfer protein gene are at increased risk to coronary heart disease in a Chinese population. Int J Cardiol. 2005;103:259-65. (Pubitemid 41132593)
17. Nagano M, Nakamura M, Kobayashi N, et al. Effort angina in a middle-aged woman with abnormally high levels of serum high-density lipoprotein cholesterol: A case of cholesteryl-ester transfer protein deficiency. Circ J. 2005;69:609-12. (Pubitemid 40745736)
18. Krauss RM, Wojnooski K, Orr J, Geany JC, Pinto CA, Liu Y, Wagner JA, Luk JM, Johnson-Levonas AQ, Anderson MS, Dansky HM. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anatrapib. J Lipid Res. 2012;53(3):540-7.
19. Niesor EJ, Chaput E, Staempfli A, et al. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis. 2011;219:761-7.
20. Fayad ZA, Mani V, Woodward M, et al. dal-PLAQUE Investigators.: Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet. 2011;378:1547-59.
21. Cannon CP. High-density lipoprotein cholesterol as the Holy Grail. JAMA. 2011;306(19):2153-5.
22. Castro-Perez J, Briand F, Gagen K, et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res. 2011;52:1965-73.
23. Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolaemia: Fasting and postprandial studies with and without pravastatin. Atherosclerosis. 1998;141(1):87-98. (Pubitemid 28539419)
24. Guerin M, Le Goff W, Duchene E, et al. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol. 2008;28(1):148-54.